Brief: Corvus Pharmaceuticals Q4 EPS USD -0.15
12/03/2026 20:01
Mar 12 (Reuters) - Corvus Pharmaceuticals Q4 net income USD -12.321 million. Q4 operating expenses USD 12.217 million Q4 basic EPS USD -0.15 Q4 operating income USD -12.217 million
Recent news on Corvus Pharmaceuticals
See all newsBrief: Corvus Pharmaceuticals Announces Initiation Of Phase 1B Clinical Trial Of Soquelitinib For Patients With Hidradenitis Suppurativa
Corvus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Toll Brothers, TG Therapeutics, CECO Environmental